Efficacy of Dendritic Cell-Based Immunotherapy Produced from Cord Blood
            <i>in vitro</i>
            and in a Humanized NSG Mouse Cancer Model

Liu, Gang; Fan, Xiaolong; Cai, Ying; Fu, Zexian; Gao, Fei; Dong, Jie; Li, Kang; Cai, Jianhui

doi:10.2217/imt-2018-0103

Cited by 9 publications

(8 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,13,17,18 Meanwhile, monocytes only take 5-6 days for maturation. [19][20][21][22][23] There are approximately 5.28% and 7.91% monocytes that can be isolated from adult PB and UCB, respectively. 16 Current trend still uses autologous peripheral blood as DC immunotherapy as summarized in Table 1.…”

Section: Monocytes Sourcesmentioning

confidence: 99%

In vitro Production of Dendritic Cells as Cancer Immunotherapy: Highlights on Sample Source, Culture Period, Differentiation and Maturation Cytokines

Facicilia,

Sartika,

Rostinawati

2023

Mol Cell Biomed Sci

View full text Add to dashboard Cite

Dendritic cells (DC) are antigen-presenting cells between innate and adaptive immune cells and commonly used as immunotherapy. Despite this promising potential, protocols detailing the specifics of the DC production are varied, affecting the potency of dendritic as immunotherapy. There are various factors affecting the production and DC potency, such as sample source, culture period, differentiation and maturation cytokines. Due to the limited number and quality of DC in humans, the monocyte could be isolated and differentiated to mature DC. The purity and viability monocytes shall be maintained to produce a high yield of DC. Negative sorting maintains the potency of DC as a therapeutic agent. Monocytes from umbilical cord blood (UCB) are naïve and can be differentiated to DC easily. Meanwhile, the tumor microenvironment (TME) may inhibit DC maturation from monocyte-derived peripheral blood. Without pro-inflammatory cytokines and a short maturation period, DC remain immature and fails to activate T cells. Long-period culture correlates with decreased DC viability and function. This review outlines several factors which can produce higher cytotoxic T cells and pro-inflammatory cytokines that might help each facility in developing its protocol to ensure the best procedure in DC production. Increasing purity and yield through close and automatic system under GMP production are mandatory to decrease risk of contamination during DC production.Keywords: differentiation cytokines, maturation cytokines, culture period, sample source, isolation technique

show abstract

Section: Monocytes Sourcesmentioning

confidence: 99%

In vitro Production of Dendritic Cells as Cancer Immunotherapy: Highlights on Sample Source, Culture Period, Differentiation and Maturation Cytokines

Facicilia,

Sartika,

Rostinawati

2023

Mol Cell Biomed Sci

View full text Add to dashboard Cite

show abstract

“…Some researchers have successfully evaluated the efficacy of various human DC vaccines in PBL-HIS models (see the Supplemental Table for references). Liu et al (2019) demonstrated that CD34-DC vaccination had prophylactic and curative antitumor effects in humanized mice. In this study, DCs derived from CD34 + stem cells using a GM-CSF/SCF culture system were much more effective than DCs derived from PBMCderived monocytes.…”

Section: Dendritic Cell Vaccines In Humanized Cancer Modelsmentioning

confidence: 99%

Humanized Mouse Models to Evaluate Cancer Immunotherapeutics

Guil‐Luna

Sedlik

Piaggio

2021

Annu. Rev. Cancer Biol.

View full text Add to dashboard Cite

Immunotherapy is at the forefront of cancer treatment. The advent of numerous novel approaches to cancer immunotherapy, including immune checkpoint antibodies, adoptive transfer of CAR (chimeric antigen receptor) T cells and TCR (T cell receptor) T cells, NK (natural killer) cells, T cell engagers, oncolytic viruses, and vaccines, is revolutionizing the treatment for different tumor types. Some are already in the clinic, and many others are underway. However, not all patients respond, resistance develops, and as available therapies multiply there is a need to further understand how they work, how to prioritize their clinical evaluation, and how to combine them. For this, animal models have been highly instrumental, and humanized mice models (i.e., immunodeficient mice engrafted with human immune and cancer cells) represent a step forward, although they have several limitations. Here, we review the different humanized models available today, the approaches to overcome their flaws, their use for the evaluation of cancer immunotherapies, and their anticipated evolution as tools to help personalized clinical decision-making.

show abstract

“…For example, a small number of low-active human T cells could not be detected in the peripheral blood until 12 weeks after HSC was implanted into mice. [28][29][30] Hu-PBL Model Hu-PBL model was established by injecting human peripheral blood lymphocytes into immunodeficient mice. It is the simplest and most economical humanized mouse model at present.…”

Section: Hu-hsc Modelmentioning

confidence: 99%

Application of Animal Models in Cancer Research: Recent Progress and Future Prospects

Wen-ling

Wang

et al. 2021

CMAR

View full text Add to dashboard Cite

Animal models refers to the animal experimental objects and related materials that can simulate human body established in medical research. As the second-largest disease in terms of morbidity and mortality after cardiovascular disease, cancer has always been the focus of human attention all over the world, which makes it a research hotspot in the medical field. At the same time, more and more animal models have been constructed and used in cancer research. With the deepening of research, the construction methods of cancer animal models are becoming more and more diverse, including chemical induction, xenotransplantation, gene programming, and so on. In recent years, patient-derived xenotransplantation (PDX) model has become a research hotspot because it can retain the microenvironment of the primary tumor and the basic characteristics of cells. Animal models can be used not only to study the biochemical and physiological processes of the occurrence and development of cancer in objects but also for the screening of cancer drugs and the exploration of gene therapy. In this paper, several main tumor animal models and the application progress of animal models in tumor research are systematically reviewed. Finally, combined with the latest progress and development trend in this field, the future research of tumor animal model was prospected.

show abstract

Efficacy of Dendritic Cell-Based Immunotherapy Produced from Cord Blood in vitro and in a Humanized NSG Mouse Cancer Model

Cited by 9 publications

References 66 publications

In vitro Production of Dendritic Cells as Cancer Immunotherapy: Highlights on Sample Source, Culture Period, Differentiation and Maturation Cytokines

In vitro Production of Dendritic Cells as Cancer Immunotherapy: Highlights on Sample Source, Culture Period, Differentiation and Maturation Cytokines

Humanized Mouse Models to Evaluate Cancer Immunotherapeutics

Application of Animal Models in Cancer Research: Recent Progress and Future Prospects

Contact Info

Product

Resources

About